Rhythm Pharmaceuticals (RYTM) Other Non-Current Liabilities (2017 - 2024)

Rhythm Pharmaceuticals (RYTM) has 4 years of Other Non-Current Liabilities data on file, last reported at $35.6 million in Q2 2024.

• Other Non-Current Liabilities for Q2 2024 came in at $35.6 million, up 2596.67% year-over-year; the trailing twelve-month figure through Jun 2024 was $35.6 million (up 2596.67% YoY), and the FY2023 annual result was $1.2 million, down 14.18% from the prior year.
• Other Non-Current Liabilities advanced to $35.6 million in Q2 2024 per RYTM's latest filing, from $660000.0 in the prior quarter.
• Over five years, Other Non-Current Liabilities peaked at $35.6 million in Q2 2024 and troughed at $1000.0 in Q1 2023.
• A 3-year average of $4.9 million and a median of $1.2 million in 2023 frame the typical range for Other Non-Current Liabilities.
• The sharpest annual moves came in 2023 and 2024: Other Non-Current Liabilities declined 16.98% in 2023, then surged 65900.0% in 2024.
• A 3-year view of Other Non-Current Liabilities shows it stood at $1.3 million in 2022, then dropped by 14.18% to $1.2 million in 2023, then surged by 2995.3% to $35.6 million in 2024.
• Business Quant data shows RYTM's Other Non-Current Liabilities at $35.6 million in Q2 2024, $660000.0 in Q1 2024, and $1.2 million in Q4 2023.